Imaging atherosclerosis with hybrid [18F]fluorodeoxyglucose positron emission tomography/computed tomography imaging: What Leonardo da Vinci could not see |
| |
Authors: | Myra S. Cocker PhD Brian Mc Ardle MB BCh J. David Spence MD Cheemun Lum MD Robert R. Hammond MD Deidre C. Ongaro B.Sc Matthew A. McDonald B.Sc Robert A. deKemp PhD Jean-Claude Tardif MD Rob S. B. Beanlands MD |
| |
Affiliation: | 1. Molecular Function and Imaging Program, Division of Cardiology, Department of Medicine, University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, ON, K1Y 4W7, Canada 2. Stroke Prevention & Atherosclerosis Research Centre, Robarts Research Institute, University of Western Ontario, 1400 Western Road, London, ON, Canada 3. Interventional & Diagnostic Neuroradiology, Department of Radiology, The Ottawa Hospital, University of Ottawa, Civic Campus, Diagnostic Imaging, K1Y 4E9, Ottawa, ON, Canada 4. Departments of Pathology and Clinical Neurological Sciences, London Health Sciences Centre and University of Western Ontario, 339 Windermere Road, N6A 5A5, London, ON, Canada 5. Montreal Heart Institute, Universit?? de Montr??al, Montreal, Canada
|
| |
Abstract: | Prodigious efforts and landmark discoveries have led toward significant advances in our understanding of atherosclerosis. Despite significant efforts, atherosclerosis continues globally to be a leading cause of mortality and reduced quality of life. With surges in the prevalence of obesity and diabetes, atherosclerosis is expected to have an even more pronounced impact upon the global burden of disease. It is imperative to develop strategies for the early detection of disease. Positron emission tomography (PET) imaging utilizing [18F]fluorodeoxyglucose (FDG) may provide a non-invasive means of characterizing inflammatory activity within atherosclerotic plaque, thus serving as a surrogate biomarker for detecting vulnerable plaque. The aim of this review is to explore the rationale for performing FDG imaging, provide an overview into the mechanism of action, and summarize findings from the early application of FDG PET imaging in the clinical setting to evaluate vascular disease. Alternative imaging biomarkers and approaches are briefly discussed. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|